Know Cancer

or
forgot password

The Effect of Vaginal Mifepristone on Reduction of Uterine Fibroids Size and the Symptoms Associated With the Fibroids - Pilot Study (Phase IIa)


Phase 2
30 Years
53 Years
Not Enrolling
Female
Uterine Fibroid, Vaginal Bleeding.

Thank you

Trial Information

The Effect of Vaginal Mifepristone on Reduction of Uterine Fibroids Size and the Symptoms Associated With the Fibroids - Pilot Study (Phase IIa)


Uterine fibroids are benign tumors of the uterus made up of smooth muscle and the
extracellular matrix proteins Collagen and Elastin. They are exceptionally common; the
cumulative incidence of a diagnosis of fibroids in women aged 25 to 45 is approximately 30
percent.

Uterine fibroids can cause abnormal uterine bleeding, dysmenorrhea, lower back pain and
non-cyclic pelvic pain. They also can contribute to symptoms related to an enlarging pelvic
mass (e.g., urinary frequency or constipation).

Uterine fibroids are also associated with an increased risk of complications of pregnancy,
and with infertility, although it is unclear whether this association is causative. Symptoms
associated with uterine fibroids can have a significant impact on quality of life, with
scores on standard measures that are comparable to those for other major chronic diseases


Inclusion Criteria:



- Uninterested in fertility during the study.

- Premenopausal status.

- Active symptoms related to uterine fibroids.

- Subjects will be obligated to use non hormonal contraceptives during the study.

Exclusion Criteria:

- Abnormal liver and renal function

- Participants with significant increase in uterine fibroids size during a short time.

- Exclusionary health problems contraindicating mifepristone included adrenal disease;
sickle cell anemia; severe liver, respiratory, or renal disease; and blood clotting
defect.

- Current use of steroids, anticoagulants, herbals, or botanicals with possible
hormonal effects.

Type of Study:

Interventional

Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Decrease of uterine fibroids volume by 25% and up.

Outcome Time Frame:

1 year

Safety Issue:

Yes

Principal Investigator

Daniel Seidman, Prof'

Investigator Role:

Principal Investigator

Investigator Affiliation:

unaffiliation

Authority:

Israel: Ministry of Health

Study ID:

bp001

NCT ID:

NCT00881140

Start Date:

April 2009

Completion Date:

July 2012

Related Keywords:

  • Uterine Fibroid
  • Vaginal Bleeding.
  • oral mifepristone
  • vaginal tablets
  • Hemorrhage
  • Leiomyoma
  • Myofibroma
  • Uterine Hemorrhage

Name

Location